journal
MENU ▼
Read by QxMD icon Read
search

Journal of the National Comprehensive Cancer Network: JNCCN

journal
https://www.readbyqxmd.com/read/28784869/oncology-research-program
#1
(no author information available yet)
No abstract text is available yet for this article.
August 2017: Journal of the National Comprehensive Cancer Network: JNCCN
https://www.readbyqxmd.com/read/28784868/acting-on-rare-driver-alterations-is-getting-a-meaningful-response-a-game-of-chance-or-scientific-rigor
#2
David R Braxton
No abstract text is available yet for this article.
August 2017: Journal of the National Comprehensive Cancer Network: JNCCN
https://www.readbyqxmd.com/read/28784867/trends-in-neoadjuvant-approaches-in-pancreatic-cancer
#3
REVIEW
Lingling Du, Andrea Wang-Gillam
Pancreatic cancer (PDAC) is an aggressive tumor type associated with development of micrometastasis at an early stage. In attempt to eradicate disseminated disease, neoadjuvant therapy has been explored in patients with resectable and borderline resectable PDAC. In large retrospective studies, neoadjuvant therapy was associated with better survival compared with upfront surgery. Previously, trials more commonly used radiotherapy (RT) with small doses of chemotherapy as radiosensitizers. Recent studies, however, have incorporated full systemic doses of chemotherapy with or without RT before surgery with the hope of achieving adequate systemic chemotherapy coverage and improving survival...
August 2017: Journal of the National Comprehensive Cancer Network: JNCCN
https://www.readbyqxmd.com/read/28784866/dna-repair-dysfunction-in-pancreatic-cancer-a-clinically-relevant-subtype-for-drug-development
#4
REVIEW
Talia Golan, Milind Javle
Pancreatic ductal adenocarcinoma (PDAC) has a dismal prognosis, with a 5-year survival rate of ≤7% across all stages. The limited success of conventional therapies for PDAC is at least partially attributable to its genetic heterogeneity. Precision targeting of known PDAC subtypes may positively affect the outcome of this disease. An important actionable subtype in this cancer is associated with DNA repair dysfunction, including cases with germline BRCA mutations. This subtype can be targeted by inhibitors of poly(ADP-ribose) polymerase (PARP)...
August 2017: Journal of the National Comprehensive Cancer Network: JNCCN
https://www.readbyqxmd.com/read/28784865/pancreatic-adenocarcinoma-version-2-2017-nccn-clinical-practice-guidelines-in-oncology
#5
Margaret A Tempero, Mokenge P Malafa, Mahmoud Al-Hawary, Horacio Asbun, Andrew Bain, Stephen W Behrman, Al B Benson, Ellen Binder, Dana B Cardin, Charles Cha, E Gabriela Chiorean, Vincent Chung, Brian Czito, Mary Dillhoff, Efrat Dotan, Cristina R Ferrone, Jeffrey Hardacre, William G Hawkins, Joseph Herman, Andrew H Ko, Srinadh Komanduri, Albert Koong, Noelle LoConte, Andrew M Lowy, Cassadie Moravek, Eric K Nakakura, Eileen M O'Reilly, Jorge Obando, Sushanth Reddy, Courtney Scaife, Sarah Thayer, Colin D Weekes, Robert A Wolff, Brian M Wolpin, Jennifer Burns, Susan Darlow
Ductal adenocarcinoma and its variants account for most pancreatic malignancies. High-quality multiphase imaging can help to preoperatively distinguish between patients eligible for resection with curative intent and those with unresectable disease. Systemic therapy is used in the neoadjuvant or adjuvant pancreatic cancer setting, as well as in the management of locally advanced unresectable and metastatic disease. Clinical trials are critical for making progress in treatment of pancreatic cancer. The NCCN Guidelines for Pancreatic Adenocarcinoma focus on diagnosis and treatment with systemic therapy, radiation therapy, and surgical resection...
August 2017: Journal of the National Comprehensive Cancer Network: JNCCN
https://www.readbyqxmd.com/read/28784864/short-and-long-term-survival-in-metastatic-pancreatic-adenocarcinoma-1993-2013
#6
Talia Golan, Tal Sella, Ofer Margalit, Uri Amit, Naama Halpern, Dan Aderka, Einat Shacham-Shmueli, Damien Urban, Yaacov Richard Lawrence
Background: During the past 2 decades, numerous clinical trials have focused on improving outcomes in patients with metastatic pancreatic cancer (mPDAC). The efficacy of new treatments has been demonstrated among highly selected patients in randomized phase III trials; hence, it is not clear to what extent these advances are reflected within the broader mPDAC population. Materials and Methods: Survival statistics were extracted from the SEER database for patients diagnosed with mPDAC between 1993 and 2013. Survival was analyzed using the Kaplan-Meier method and proportional hazard models...
August 2017: Journal of the National Comprehensive Cancer Network: JNCCN
https://www.readbyqxmd.com/read/28784863/costs-and-benefits-of-extended-endocrine-strategies-for-premenopausal-breast-cancer
#7
Janice S Kwon, Gary Pansegrau, Melica Nourmoussavi, Geoffrey L Hammond, Mark S Carey
Background: After completing 5 years of adjuvant tamoxifen, women with estrogen receptor (ER)-positive breast cancer benefit from 5 more years of endocrine therapy, either with tamoxifen or an aromatase inhibitor (AI). For premenopausal women, ovarian ablation (OA) would be required before starting an AI (OA/AI). According to the SOFT/TEXT studies, OA/AI improves 5-year disease-free survival compared with tamoxifen alone, suggesting that OA/AI could be superior to tamoxifen as extended endocrine therapy. The long-term costs and consequences of premature menopause from OA are unknown, but could be estimated through a cost-effectiveness analysis...
August 2017: Journal of the National Comprehensive Cancer Network: JNCCN
https://www.readbyqxmd.com/read/28784862/the-evolution-of-metastatic-colorectal-cancer-clinical-trials-application-of-the-asco-framework-for-assessing-value
#8
Doreen A Ezeife, Sunil Parimi, Ellen R Cusano, Matthew K Smith, Tony H Truong, Soundouss Raissouni, Yongtao Lin, Jose G Monzon, Haocheng Li, Vincent C Tam, Patricia A Tang
Background: Phase III trials in metastatic colorectal cancer (mCRC) have collectively led to progressive advancements in patient outcomes over the past decades. This study characterizes the evolution of mCRC phase III trials through assessing the value of cancer therapy, as measured by the ASCO Value Framework. Methods: Phase III trial results of systemic therapy for mCRC published between 1980 and 2015 were identified, and their outcome, statistical significance, journal impact factor, and citation by the 2016 NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for CRC were recorded...
August 2017: Journal of the National Comprehensive Cancer Network: JNCCN
https://www.readbyqxmd.com/read/28784861/race-and-sex-based-disparities-in-the-therapy-and-outcomes-of-squamous-cell-carcinoma-of-the-anus
#9
Nivedita Arora, Arjun Gupta, Hong Zhu, Alana Christie, Jeffrey J Meyer, Saad A Khan, Muhammad S Beg
Background: Squamous cell carcinoma of the anus (SCCA) is one of the few cancers with an increasing incidence in the United States. We aimed to characterize race- and sex-based disparities in receipt of therapy and overall survival (OS) of SCCA using the SEER database. Methods: Cases of locoregional SCCA (T2-T4 any N M0) diagnosed between 2000 and 2012 in the SEER database were included. Demographics, tumor characteristics, type of therapy, and outcomes were extracted. Univariable and multivariable Cox proportional hazard models were constructed to test factors associated with OS...
August 2017: Journal of the National Comprehensive Cancer Network: JNCCN
https://www.readbyqxmd.com/read/28784860/nccn-guidelines-insights-palliative-care-version-2-2017
#10
Maria Dans, Thomas Smith, Anthony Back, Justin N Baker, Jessica R Bauman, Anna C Beck, Susan Block, Toby Campbell, Amy A Case, Shalini Dalal, Howard Edwards, Thomas R Fitch, Jennifer Kapo, Jean S Kutner, Elizabeth Kvale, Charles Miller, Sumathi Misra, William Mitchell, Diane G Portman, David Spiegel, Linda Sutton, Eytan Szmuilowicz, Jennifer Temel, Roma Tickoo, Susan G Urba, Elizabeth Weinstein, Finly Zachariah, Mary Anne Bergman, Jillian L Scavone
The NCCN Guidelines for Palliative Care provide interdisciplinary recommendations on palliative care for patients with cancer. These NCCN Guidelines Insights summarize and provide context for the updated guidelines recommendations regarding hospice and end-of-life (EOL) care. Updates for 2017 include revisions to and restructuring of the algorithms that address important EOL concerns. These recommendations were revised to provide clearer guidance for oncologists as they care for patients with cancer who are approaching the transition to EOL care...
August 2017: Journal of the National Comprehensive Cancer Network: JNCCN
https://www.readbyqxmd.com/read/28784859/neoadjuvant-treatment-with-trastuzumab-and-folfox-induces-a-complete-pathologic-response-in-a-metastatic-erbb2-her2-amplified-duodenal-cancer
#11
Ahmad Hamad, Aatur D Singhi, Nathan Bahary, Kevin McGrath, Rula Amarin, Herbert J Zeh, Amer H Zureikat
Overexpression of HER2 protein and amplification of the ERBB2 gene has been observed in various adenocarcinomas, providing a therapeutic target that can be used to extend the survival of a select cohort of patients. Anti-HER2 therapy has been successfully applied to gastric and colorectal cancers, but its use and potential benefit in small intestinal carcinomas is not well characterized. We applied anti-HER2 therapy to an ERBB2-amplified advanced duodenal adenocarcinoma, adding trastuzumab to FOLFOX in the neoadjuvant setting...
August 2017: Journal of the National Comprehensive Cancer Network: JNCCN
https://www.readbyqxmd.com/read/28784858/targeted-mapk-pathway-inhibitors-in-patients-with-disseminated-pilocytic-astrocytomas
#12
Anastasia Drobysheva, Laura J Klesse, Daniel C Bowers, Veena Rajaram, Dinesh Rakheja, Charles F Timmons, Jason Wang, Korgun Koral, Lynn Gargan, Erica Ramos, Jason Y Park
This report presents a series of 5 pediatric patients with disseminated pilocytic astrocytomas and frequent nonfusion activating mutations. Genetic variants in these patients' tumors include BRAF p.Val600Glu, BRAF p.Val600Asp, and KRAS p.Gly60_Gln62ins7. The 2 patients with BRAF-mutated tumors were treated with dabrafenib or a combination of dabrafenib plus trametinib. The patients had either near complete resolution of the primary tumor (BRAF p.Val600Glu) or a stable primary tumor (BRAF p.Val600Asp). Both patients showed improvement in leptomeningeal dissemination without significant toxicity...
August 2017: Journal of the National Comprehensive Cancer Network: JNCCN
https://www.readbyqxmd.com/read/28784857/to-the-editor-how-do-we-solve-this-confusion
#13
LETTER
(no author information available yet)
No abstract text is available yet for this article.
August 2017: Journal of the National Comprehensive Cancer Network: JNCCN
https://www.readbyqxmd.com/read/28784856/when-it-s-really-good-we-know-it
#14
Margaret Tempero
No abstract text is available yet for this article.
August 2017: Journal of the National Comprehensive Cancer Network: JNCCN
https://www.readbyqxmd.com/read/28687585/nccn-news
#15
(no author information available yet)
No abstract text is available yet for this article.
July 2017: Journal of the National Comprehensive Cancer Network: JNCCN
https://www.readbyqxmd.com/read/28687583/abdominal-pain-with-boring-like-character-the-revolution-is-yet-to-come
#16
Xavier Llor
No abstract text is available yet for this article.
July 2017: Journal of the National Comprehensive Cancer Network: JNCCN
https://www.readbyqxmd.com/read/28687582/role-of-alternative-donor-allogeneic-transplants-in-the-therapy-of-acute-myeloid-leukemia
#17
REVIEW
Hany Elmariah, Keith W Pratz
Adult acute myeloid leukemia (AML) is often associated with a poor prognosis, with allogeneic transplantation representing the greatest chance of cure for eligible patients. Historically, the preferred donor source is a human leukocyte antigen-matched blood relative, although only approximately 30% of patients have access to such a donor. Alternative donor sources, including matched unrelated donors, umbilical cord blood, and haploidentical related donors, are available for almost every patient and are increasingly being used for patients without a matched related donor...
July 2017: Journal of the National Comprehensive Cancer Network: JNCCN
https://www.readbyqxmd.com/read/28687581/acute-myeloid-leukemia-version-3-2017-nccn-clinical-practice-guidelines-in-oncology
#18
Margaret R O'Donnell, Martin S Tallman, Camille N Abboud, Jessica K Altman, Frederick R Appelbaum, Daniel A Arber, Vijaya Bhatt, Dale Bixby, William Blum, Steven E Coutre, Marcos De Lima, Amir T Fathi, Melanie Fiorella, James M Foran, Steven D Gore, Aric C Hall, Patricia Kropf, Jeffrey Lancet, Lori J Maness, Guido Marcucci, Michael G Martin, Joseph O Moore, Rebecca Olin, Deniz Peker, Daniel A Pollyea, Keith Pratz, Farhad Ravandi, Paul J Shami, Richard M Stone, Stephen A Strickland, Eunice S Wang, Matthew Wieduwilt, Kristina Gregory, Ndiya Ogba
Acute myeloid leukemia (AML) is the most common form of acute leukemia among adults and accounts for the largest number of annual deaths due to leukemias in the United States. This portion of the NCCN Guidelines for AML focuses on management and provides recommendations on the workup, diagnostic evaluation, and treatment options for younger (age <60 years) and older (age ≥60 years) adult patients.
July 2017: Journal of the National Comprehensive Cancer Network: JNCCN
https://www.readbyqxmd.com/read/28687580/accuracy-of-referring-provider-and-endoscopist-impressions-of-colonoscopy-indication
#19
Mariam Naveed, Meredith Clary, Chul Ahn, Nisa Kubiliun, Deepak Agrawal, Byron Cryer, Caitlin Murphy, Amit G Singal
Background: Referring provider and endoscopist impressions of colonoscopy indication are used for clinical care, reimbursement, and quality reporting decisions; however, the accuracy of these impressions is unknown. This study assessed the sensitivity, specificity, positive and negative predictive value, and overall accuracy of methods to classify colonoscopy indication, including referring provider impression, endoscopist impression, and administrative algorithm compared with gold standard chart review. Methods: We randomly sampled 400 patients undergoing a colonoscopy at a Veterans Affairs health system between January 2010 and December 2010...
July 2017: Journal of the National Comprehensive Cancer Network: JNCCN
https://www.readbyqxmd.com/read/28687579/validation-of-the-8th-edition-of-the-uicc-ajcc-staging-system-for-nasopharyngeal-carcinoma-from-endemic-areas-in-the-intensity-modulated-radiotherapy-era
#20
Ling-Long Tang, Yu-Pei Chen, Yan-Ping Mao, Zi-Xian Wang, Rui Guo, Lei Chen, Li Tian, Ai-Hua Lin, Li Li, Ying Sun, Jun Ma
Background: In this study, we evaluated the 8th edition of the Union for International Cancer Control (UICC)/AJCC staging system for nasopharyngeal carcinoma (NPC) in an endemic area, with the aim of validating its applicability and providing further information for future refinements. Methods: A total of 1,790 patients with newly diagnosed, non-distant metastatic, histologically proven NPC treated with intensity-modulated radiotherapy (IMRT) were retrospectively reviewed. The performance of various staging systems was compared using the Akaike information criterion (AIC) and Harrell's concordance index (c-index)...
July 2017: Journal of the National Comprehensive Cancer Network: JNCCN
journal
journal
40348
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"